Scrotal cutaneous side effects of sunitinib

New England Journal of Medicine

Volumn 359, Issue 9, 2008, Pages 976-

  Niculescu, Liviu ^a   Hariharan, Subramanian ^a   Charles, Lorna ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; SUNITINIB;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; HAIR COLOR; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LETTER; PRIORITY JOURNAL; PSORIASIS; RASH; SIDE EFFECT; SKIN DISCOLORATION;

EID: 50449100464     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Sutent USPI. New York: Pfizer, May 2008 (package insert).
2. Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007;149:103-6.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.